Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780.

Nammalwar B, Bunce RA, Berlin KD, Benbrook DM, Toal C.

Eur J Med Chem. 2019 May 15;170:16-27. doi: 10.1016/j.ejmech.2019.03.010. Epub 2019 Mar 7.

PMID:
30878829
2.

Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2.

Watts FM Jr, Pouland T, Bunce RA, Berlin KD, Benbrook DM, Mashayekhi M, Bhandari D, Zhou D.

Eur J Med Chem. 2018 Oct 5;158:720-732. doi: 10.1016/j.ejmech.2018.09.036. Epub 2018 Sep 14.

PMID:
30245396
3.

Label-Free Real-Time Microarray Imaging of Cancer Protein-Protein Interactions and Their Inhibition by Small Molecules.

Walgama C, Al Mubarak ZH, Zhang B, Akinwale M, Pathiranage A, Deng J, Berlin KD, Benbrook DM, Krishnan S.

Anal Chem. 2016 Mar 15;88(6):3130-5. doi: 10.1021/acs.analchem.5b04234. Epub 2016 Feb 29.

PMID:
26886845
4.

Evaluation of New Dihydrophthalazine-Appended 2,4-Diaminopyrimidines against Bacillus anthracis: Improved Syntheses Using a New Pincer Complex.

Muddala NP, Nammalwar B, Selvaraju S, Bourne CR, Henry M, Bunce RA, Berlin KD, Barrow EW, Barrow WW.

Molecules. 2015 Apr 21;20(4):7222-44. doi: 10.3390/molecules20047222.

5.

Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line.

Gnanasekaran KK, Benbrook DM, Nammalwar B, Thavathiru E, Bunce RA, Berlin KD.

Eur J Med Chem. 2015;96:209-17. doi: 10.1016/j.ejmech.2015.03.070. Epub 2015 Apr 4.

PMID:
25880346
6.

Modified 2,4-diaminopyrimidine-based dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis.

Nammalwar B, Bourne CR, Wakeham N, Bourne PC, Barrow EW, Muddala NP, Bunce RA, Berlin KD, Barrow WW.

Bioorg Med Chem. 2015 Jan 1;23(1):203-11. doi: 10.1016/j.bmc.2014.11.009. Epub 2014 Nov 11.

7.

Synthesis and biological evaluation of 2,4-diaminopyrimidine-based antifolate drugs against Bacillus anthracis.

Nammalwar B, Muddala NP, Bourne CR, Henry M, Bourne PC, Bunce RA, Barrow EW, Berlin KD, Barrow WW.

Molecules. 2014 Mar 17;19(3):3231-46. doi: 10.3390/molecules19033231.

8.

The structure and competitive substrate inhibition of dihydrofolate reductase from Enterococcus faecalis reveal restrictions to cofactor docking.

Bourne CR, Wakeham N, Webb N, Nammalwar B, Bunce RA, Berlin KD, Barrow WW.

Biochemistry. 2014 Feb 25;53(7):1228-38. doi: 10.1021/bi401104t. Epub 2014 Feb 11.

9.

SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.

Benbrook DM, Nammalwar B, Long A, Matsumoto H, Singh A, Bunce RA, Berlin KD.

Invest New Drugs. 2014 Jun;32(3):412-23. doi: 10.1007/s10637-013-0041-x. Epub 2013 Nov 20.

10.

Comparative Study of the Frech Catalyst with Two Conventional Catalysts in the Heck Synthesis of 2,4-Diaminopyrimidine-based Antibiotics.

Nammalwar B, Bunce RA, Berlin KD, Bourne CR, Bourne PC, Barrow EW, Barrow WW.

Org Prep Proced Int. 2013;45(1):66-71. No abstract available.

11.

Structure-activity relationship for enantiomers of potent inhibitors of B. anthracis dihydrofolate reductase.

Bourne CR, Wakeham N, Nammalwar B, Tseitin V, Bourne PC, Barrow EW, Mylvaganam S, Ramnarayan K, Bunce RA, Berlin KD, Barrow WW.

Biochim Biophys Acta. 2013 Jan;1834(1):46-52. doi: 10.1016/j.bbapap.2012.09.001. Epub 2012 Sep 20.

12.

Inhibition of bacterial dihydrofolate reductase by 6-alkyl-2,4-diaminopyrimidines.

Nammalwar B, Bourne CR, Bunce RA, Wakeham N, Bourne PC, Ramnarayan K, Mylvaganam S, Berlin KD, Barrow EW, Barrow WW.

ChemMedChem. 2012 Nov;7(11):1974-82. doi: 10.1002/cmdc.201200291. Epub 2012 Aug 28.

13.

Synthesis and biological activity of substituted 2,4-diaminopyrimidines that inhibit Bacillus anthracis.

Nammalwar B, Bunce RA, Berlin KD, Bourne CR, Bourne PC, Barrow EW, Barrow WW.

Eur J Med Chem. 2012 Aug;54:387-96. doi: 10.1016/j.ejmech.2012.05.018. Epub 2012 May 22.

14.

Classifying compound mechanism of action for linking whole cell phenotypes to molecular targets.

Bourne CR, Wakeham N, Bunce RA, Nammalwar B, Berlin KD, Barrow WW.

J Mol Recognit. 2012 Apr;25(4):216-23. doi: 10.1002/jmr.2174.

15.

Microwave-assisted Heck Synthesis of Substituted 2,4-Diaminopyrimidine-based Antibiotics.

Nammalwar B, Bunce RA, Berlin KD, Bourne CR, Bourne PC, Barrow EW, Barrow WW.

Org Prep Proced Int. 2012;44(3):281-287. No abstract available.

16.

Approaches to Iodinated Derivatives of Vanillin and Isovanillin.

Nammalwar B, Bunce RA, Berlin KD, Bourne CR, Bourne PC, Barrow EW, Barrow WW.

Org Prep Proced Int. 2012;44(2):146-152. No abstract available.

17.

Development of flexible-heteroarotinoids for kidney cancer.

Liu T, Masamha CP, Chengedza S, Berlin KD, Lightfoot S, He F, Benbrook DM.

Mol Cancer Ther. 2009 May;8(5):1227-38. doi: 10.1158/1535-7163.MCT-08-1069. Epub 2009 May 5.

18.

Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity.

Bourne CR, Bunce RA, Bourne PC, Berlin KD, Barrow EW, Barrow WW.

Antimicrob Agents Chemother. 2009 Jul;53(7):3065-73. doi: 10.1128/AAC.01666-08. Epub 2009 Apr 13.

19.

Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells.

Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, Khuri FR, Sun SY.

Mol Cancer Ther. 2008 Nov;7(11):3556-65. doi: 10.1158/1535-7163.MCT-08-0648.

20.

CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.

Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY.

Cancer Res. 2008 Jul 1;68(13):5335-44. doi: 10.1158/0008-5472.CAN-07-6209.

Supplemental Content

Loading ...
Support Center